{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T09:33:11Z","timestamp":1784539991030,"version":"3.55.0"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T00:00:00Z","timestamp":1700870400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s00277-023-05557-z","type":"journal-article","created":{"date-parts":[[2023,11,25]],"date-time":"2023-11-25T10:02:17Z","timestamp":1700906537000},"page":"843-854","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Reduced-intensity allogenic transplantation for children and adolescents with Philadelphia chromosome-positive acute lymphoblastic leukemia"],"prefix":"10.1007","volume":"103","author":[{"given":"Hisashi","family":"Ishida","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Arakawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiichiro","family":"Hasegawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ikuya","family":"Usami","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Hashii","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yasuyuki","family":"Arai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Nishiwaki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dai","family":"Keino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keisuke","family":"Kato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maho","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nao","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukiyasu","family":"Ozawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keiko","family":"Okada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moe","family":"Hidaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuki","family":"Yuza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masatsugu","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kenichiro","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junko","family":"Takita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiyuki","family":"Kosaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoto","family":"Fujita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junji","family":"Tanaka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshiko","family":"Atsuta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5727-4470","authenticated-orcid":false,"given":"Toshihiko","family":"Imamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,11,25]]},"reference":[{"key":"5557_CR1","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMra023001","volume":"350","author":"C-H Pui","year":"2004","unstructured":"Pui C-H, Relling MV, Downing JR (2004) Acute lymphoblastic leukemia. New England J Med 350:1535\u20131548. https:\/\/doi.org\/10.1056\/NEJMra023001","journal-title":"New England J Med"},{"key":"5557_CR2","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJM200004063421402","volume":"342","author":"M Aric\u00f2","year":"2000","unstructured":"Aric\u00f2 M, Valsecchi MG, Camitta B et al (2000) Outcome of treatment in children with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. New England J Med 342:998\u20131006. https:\/\/doi.org\/10.1056\/NEJM200004063421402","journal-title":"New England J Med"},{"key":"5557_CR3","doi-asserted-by":"publisher","first-page":"4755","DOI":"10.1200\/JCO.2010.30.1325","volume":"28","author":"M Aric\u00f2","year":"2010","unstructured":"Aric\u00f2 M, Schrappe M, Hunger SP et al (2010) Clinical outcome of children with newly diagnosed Philadelphia chromosome\u2013positive acute lymphoblastic leukemia treated between 1995 and 2005. J Clin Oncol 28:4755\u20134761. https:\/\/doi.org\/10.1200\/JCO.2010.30.1325","journal-title":"J Clin Oncol"},{"key":"5557_CR4","doi-asserted-by":"publisher","first-page":"5175","DOI":"10.1200\/JCO.2008.21.2514","volume":"27","author":"KR Schultz","year":"2009","unstructured":"Schultz KR, Bowman WP, Aledo A et al (2009) Improved early event-free survival with imatinib in Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a children\u2019s oncology group study. J Clin Oncol 27:5175\u20135181. https:\/\/doi.org\/10.1200\/JCO.2008.21.2514","journal-title":"J Clin Oncol"},{"key":"5557_CR5","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/S1470-2045(12)70377-7","volume":"13","author":"A Biondi","year":"2012","unstructured":"Biondi A, Schrappe M, de Lorenzo P et al (2012) Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study. Lancet Oncol 13:936\u2013945. https:\/\/doi.org\/10.1016\/S1470-2045(12)70377-7","journal-title":"Lancet Oncol"},{"key":"5557_CR6","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1038\/leu.2014.30","volume":"28","author":"KR Schultz","year":"2014","unstructured":"Schultz KR, Carroll A, Heerema NA et al (2014) Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children\u2019s Oncology Group Study AALL0031. Leukemia 28:1467\u20131471. https:\/\/doi.org\/10.1038\/leu.2014.30","journal-title":"Leukemia"},{"key":"5557_CR7","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1002\/cam4.383","volume":"4","author":"A Manabe","year":"2015","unstructured":"Manabe A, Kawasaki H, Shimada H et al (2015) Imatinib use immediately before stem cell transplantation in children with Philadelphia chromosome-positive acute lymphoblastic leukemia: results from Japanese Pediatric Leukemia\/Lymphoma Study Group (JPLSG) Study Ph + ALL04. Cancer Med 4:682\u2013689. https:\/\/doi.org\/10.1002\/cam4.383","journal-title":"Cancer Med"},{"key":"5557_CR8","doi-asserted-by":"publisher","first-page":"e641","DOI":"10.1016\/S2352-3026(18)30173-X","volume":"5","author":"A Biondi","year":"2018","unstructured":"Biondi A, Gandemer V, De Lorenzo P et al (2018) Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial. Lancet Haematol 5:e641\u2013e652. https:\/\/doi.org\/10.1016\/S2352-3026(18)30173-X","journal-title":"Lancet Haematol"},{"key":"5557_CR9","doi-asserted-by":"publisher","first-page":"2306","DOI":"10.1200\/JCO.2017.76.7228","volume":"36","author":"WB Slayton","year":"2018","unstructured":"Slayton WB, Schultz KR, Kairalla JA et al (2018) Dasatinib plus intensive chemotherapy in children, adolescents, and young adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: results of Children\u2019s Oncology Group Trial AALL0622. J Clin Oncol 36:2306\u20132314. https:\/\/doi.org\/10.1200\/JCO.2017.76.7228","journal-title":"J Clin Oncol"},{"key":"5557_CR10","doi-asserted-by":"publisher","first-page":"1541","DOI":"10.1056\/NEJMra1400972","volume":"373","author":"SP Hunger","year":"2015","unstructured":"Hunger SP, Mullighan CG (2015) Acute lymphoblastic leukemia in children. New England J Med 373:1541\u20131552. https:\/\/doi.org\/10.1056\/NEJMra1400972","journal-title":"New England J Med"},{"key":"5557_CR11","doi-asserted-by":"publisher","first-page":"2524","DOI":"10.3324\/haematol.2020.247031","volume":"105","author":"H Inaba","year":"2020","unstructured":"Inaba H, Mullighan CG (2020) Pediatric acute lymphoblastic leukemia. Haematologica 105:2524\u20132539. https:\/\/doi.org\/10.3324\/haematol.2020.247031","journal-title":"Haematologica"},{"key":"5557_CR12","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1002\/cncr.31874","volume":"125","author":"J Yoon","year":"2019","unstructured":"Yoon J, Min GJ, Park S et al (2019) Minimal residual disease\u2013based long-term efficacy of reduced-intensity conditioning versus myeloablative conditioning for adult Philadelphia-positive acute lymphoblastic leukemia. Cancer 125:873\u2013883. https:\/\/doi.org\/10.1002\/cncr.31874","journal-title":"Cancer"},{"key":"5557_CR13","doi-asserted-by":"publisher","first-page":"1317","DOI":"10.1038\/s41409-020-0951-0","volume":"55","author":"Y Akahoshi","year":"2020","unstructured":"Akahoshi Y, Nishiwaki S, Arai Y et al (2020) Reduced-intensity conditioning is a reasonable alternative for Philadelphia chromosome-positive acute lymphoblastic leukemia among elderly patients who have achieved negative minimal residual disease: a report from the Adult Acute Lymphoblastic Leukemia W. Bone Marrow Transplant 55:1317\u20131325. https:\/\/doi.org\/10.1038\/s41409-020-0951-0","journal-title":"Bone Marrow Transplant"},{"key":"5557_CR14","doi-asserted-by":"publisher","first-page":"658","DOI":"10.1038\/leu.2013.253","volume":"28","author":"V Bachanova","year":"2014","unstructured":"Bachanova V, Marks DI, Zhang M-J et al (2014) Ph+ ALL patients in first complete remission have similar survival after reduced intensity and myeloablative allogeneic transplantation: impact of tyrosine kinase inhibitor and minimal residual disease. Leukemia 28:658\u2013665. https:\/\/doi.org\/10.1038\/leu.2013.253","journal-title":"Leukemia"},{"key":"5557_CR15","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1007\/s11912-018-0719-5","volume":"20","author":"A Lawitschka","year":"2018","unstructured":"Lawitschka A, Peters C (2018) Long-term effects of myeloablative allogeneic hematopoietic stem cell transplantation in pediatric patients with acute lymphoblastic leukemia. Curr Oncol Rep 20:74. https:\/\/doi.org\/10.1007\/s11912-018-0719-5","journal-title":"Curr Oncol Rep"},{"key":"5557_CR16","doi-asserted-by":"publisher","first-page":"3418","DOI":"10.1200\/JCO.20.00493","volume":"38","author":"SB Dixon","year":"2020","unstructured":"Dixon SB, Chen Y, Yasui Y et al (2020) Reduced morbidity and mortality in survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. J Clin Oncol 38:3418\u20133429. https:\/\/doi.org\/10.1200\/JCO.20.00493","journal-title":"J Clin Oncol"},{"key":"5557_CR17","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1007\/s12185-015-1894-x","volume":"103","author":"Y Atsuta","year":"2016","unstructured":"Atsuta Y (2016) Introduction of Transplant Registry Unified Management Program 2 (TRUMP2): scripts for TRUMP data analyses, part I (variables other than HLA-related data). Int J Hematol 103:3\u201310. https:\/\/doi.org\/10.1007\/s12185-015-1894-x","journal-title":"Int J Hematol"},{"key":"5557_CR18","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/0021-9681(60)90137-5","volume":"11","author":"CG Zubrod","year":"1960","unstructured":"Zubrod CG, Schneiderman M, Frei E et al (1960) Appraisal of methods for the study of chemotherapy of cancer in man: comparative therapeutic trial of nitrogen mustard and triethylene thiophosphoramide. J Chronic Dis 11:7\u201333. https:\/\/doi.org\/10.1016\/0021-9681(60)90137-5","journal-title":"J Chronic Dis"},{"key":"5557_CR19","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1016\/j.bbmt.2008.12.497","volume":"15","author":"S Giralt","year":"2009","unstructured":"Giralt S, Ballen K, Rizzo D et al (2009) Reduced-intensity conditioning regimen workshop: defining the dose spectrum. Report of a Workshop Convened by the Center for International Blood and Marrow Transplant Research. Biol Blood Marrow Trans 15:367\u2013369. https:\/\/doi.org\/10.1016\/j.bbmt.2008.12.497","journal-title":"Biol Blood Marrow Trans"},{"key":"5557_CR20","first-page":"825","volume":"15","author":"D Przepiorka","year":"1995","unstructured":"Przepiorka D, Weisdorf D, Martin P et al (1995) 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant 15:825\u20138","journal-title":"Bone Marrow Transplant"},{"key":"5557_CR21","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1053\/bbmt.2003.50026","volume":"9","author":"SJ Lee","year":"2003","unstructured":"Lee SJ, Vogelsang G, Flowers MED (2003) Chronic graft-versus-host disease. Biol Blood Marrow Trans 9:215\u2013233. https:\/\/doi.org\/10.1053\/bbmt.2003.50026","journal-title":"Biol Blood Marrow Trans"},{"key":"5557_CR22","doi-asserted-by":"publisher","first-page":"2009","DOI":"10.1016\/j.bbmt.2018.06.006","volume":"24","author":"Y Akahoshi","year":"2018","unstructured":"Akahoshi Y, Mizuta S, Shimizu H et al (2018) Additional cytogenetic abnormalities with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia on allogeneic stem cell transplantation in the tyrosine kinase inhibitor era. Biol Blood Marrow Trans 24:2009\u20132016. https:\/\/doi.org\/10.1016\/j.bbmt.2018.06.006","journal-title":"Biol Blood Marrow Trans"},{"key":"5557_CR23","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1182\/blood-2013-11-538728","volume":"123","author":"S Mizuta","year":"2014","unstructured":"Mizuta S, Matsuo K, Nishiwaki S et al (2014) Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL\u2013positive acute lymphoblastic leukemia. Blood 123:2325\u20132332. https:\/\/doi.org\/10.1182\/blood-2013-11-538728","journal-title":"Blood"},{"key":"5557_CR24","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1182\/bloodadvances.2020003536","volume":"5","author":"S Nishiwaki","year":"2021","unstructured":"Nishiwaki S, Akahoshi Y, Mizuta S et al (2021) Measurable residual disease affects allogeneic hematopoietic cell transplantation in Ph+ ALL during both CR1 and CR2. Blood Adv 5:584\u2013592. https:\/\/doi.org\/10.1182\/bloodadvances.2020003536","journal-title":"Blood Adv"},{"key":"5557_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics. Bone Marrow Transplant 48:452\u2013458. https:\/\/doi.org\/10.1038\/bmt.2012.244","journal-title":"Bone Marrow Transplant"},{"key":"5557_CR26","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1007\/s12185-015-1883-0","volume":"102","author":"S Takashima","year":"2015","unstructured":"Takashima S, Miyamoto T, Kamimura T et al (2015) Effects of conditioning intensity in allogeneic stem cell transplantation for Philadelphia chromosome-positive acute lymphoblastic leukemia. Int J Hematol 102:689\u2013696. https:\/\/doi.org\/10.1007\/s12185-015-1883-0","journal-title":"Int J Hematol"},{"key":"5557_CR27","doi-asserted-by":"publisher","first-page":"1190","DOI":"10.1038\/s41409-020-01173-x","volume":"56","author":"K Hirschb\u00fchl","year":"2021","unstructured":"Hirschb\u00fchl K, Labopin M, Houhou M et al (2021) Second- and third-generation tyrosine kinase inhibitors for Philadelphia-positive adult acute lymphoblastic leukemia relapsing post allogeneic stem cell transplantation\u2014a registry study on behalf of the EBMT Acute Leukemia Working Party. Bone Marrow Transplant 56:1190\u20131199. https:\/\/doi.org\/10.1038\/s41409-020-01173-x","journal-title":"Bone Marrow Transplant"},{"key":"5557_CR28","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1111\/bjh.13896","volume":"172","author":"K Bleckmann","year":"2016","unstructured":"Bleckmann K, Schrappe M (2016) Advances in therapy for Philadelphia-positive acute lymphoblastic leukaemia of childhood and adolescence. Br J Haematol 172:855\u2013869. https:\/\/doi.org\/10.1111\/bjh.13896","journal-title":"Br J Haematol"},{"key":"5557_CR29","doi-asserted-by":"publisher","first-page":"e28543","DOI":"10.1002\/pbc.28543","volume":"67","author":"WB Slayton","year":"2020","unstructured":"Slayton WB, Schultz KR, Silverman LB, Hunger SP (2020) How we approach Philadelphia chromosome-positive acute lymphoblastic leukemia in children and young adults. Pediatr Blood Cancer 67:e28543. https:\/\/doi.org\/10.1002\/pbc.28543","journal-title":"Pediatr Blood Cancer"},{"key":"5557_CR30","doi-asserted-by":"publisher","first-page":"392","DOI":"10.3324\/haematol.2014.116954","volume":"100","author":"E Brissot","year":"2015","unstructured":"Brissot E, Labopin M, Beckers MM et al (2015) Tyrosine kinase inhibitors improve long-term outcome of allogeneic hematopoietic stem cell transplantation for adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia. Haematologica 100:392\u2013399. https:\/\/doi.org\/10.3324\/haematol.2014.116954","journal-title":"Haematologica"},{"key":"5557_CR31","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/cncr.30130","volume":"122","author":"S Giebel","year":"2016","unstructured":"Giebel S, Czyz A, Ottmann O et al (2016) Use of tyrosine kinase inhibitors to prevent relapse after allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia: a position statement of the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Cancer 122:2941\u20132951. https:\/\/doi.org\/10.1002\/cncr.30130","journal-title":"Cancer"},{"key":"5557_CR32","doi-asserted-by":"publisher","first-page":"624","DOI":"10.1182\/bloodadvances.2021004607","volume":"6","author":"I Sugiura","year":"2022","unstructured":"Sugiura I, Doki N, Hata T et al (2022) Dasatinib-based 2-step induction for adults with Philadelphia chromosome\u2013positive acute lymphoblastic leukemia. Blood Adv 6:624\u2013636. https:\/\/doi.org\/10.1182\/bloodadvances.2021004607","journal-title":"Blood Adv"},{"key":"5557_CR33","doi-asserted-by":"publisher","first-page":"1254","DOI":"10.1038\/leu.2012.352","volume":"27","author":"H Pfeifer","year":"2013","unstructured":"Pfeifer H, Wassmann B, Bethge W et al (2013) Randomized comparison of prophylactic and minimal residual disease-triggered imatinib after allogeneic stem cell transplantation for BCR\u2013ABL1-positive acute lymphoblastic leukemia. Leukemia 27:1254\u20131262. https:\/\/doi.org\/10.1038\/leu.2012.352","journal-title":"Leukemia"},{"key":"5557_CR34","doi-asserted-by":"publisher","first-page":"1794","DOI":"10.3324\/haematol.2020.268839","volume":"106","author":"N Gagelmann","year":"2021","unstructured":"Gagelmann N, Kr\u00f6ger N (2021) Dose intensity for conditioning in allogeneic hematopoietic cell transplantation: can we recommend \u201cwhen and for whom\u201d in 2021? Haematologica 106:1794\u20131804. https:\/\/doi.org\/10.3324\/haematol.2020.268839","journal-title":"Haematologica"},{"key":"5557_CR35","doi-asserted-by":"publisher","first-page":"1289","DOI":"10.1002\/pbc.22263","volume":"53","author":"MJ Burke","year":"2009","unstructured":"Burke MJ, Cao Q, Trotz B et al (2009) Allogeneic hematopoietic cell transplantation (allogeneic HCT) for treatment of pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL). Pediatr Blood Cancer 53:1289\u20131294. https:\/\/doi.org\/10.1002\/pbc.22263","journal-title":"Pediatr Blood Cancer"},{"key":"5557_CR36","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/1756-8722-5-29","volume":"5","author":"H Chen","year":"2012","unstructured":"Chen H, Liu K, Xu L et al (2012) Administration of imatinib after allogeneic hematopoietic stem cell transplantation may improve disease-free survival for patients with Philadelphia chromosome-positive acute lymphobla stic leukemia. J Hematol Oncol 5:29. https:\/\/doi.org\/10.1186\/1756-8722-5-29","journal-title":"J Hematol Oncol"},{"key":"5557_CR37","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.bbmt.2011.08.011","volume":"18","author":"P Kebriaei","year":"2012","unstructured":"Kebriaei P, Saliba R, Rondon G et al (2012) Long-term follow-up of allogeneic hematopoietic stem cell transplantation for patients with Philadelphia chromosome-positive acute lymphoblastic leukemia: impact of tyrosine kinase inhibitors on treatment outcomes. Biol Blood Marrow Trans 18:584\u2013592. https:\/\/doi.org\/10.1016\/j.bbmt.2011.08.011","journal-title":"Biol Blood Marrow Trans"},{"key":"5557_CR38","doi-asserted-by":"publisher","first-page":"472","DOI":"10.1016\/j.bbmt.2019.10.017","volume":"26","author":"Z DeFilipp","year":"2020","unstructured":"DeFilipp Z, Ancheta R, Liu Y et al (2020) Maintenance tyrosine kinase inhibitors following allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia: a Center for International Blood and Marrow Transplant Research Study. Biol Blood Marrow Trans 26:472\u2013479. https:\/\/doi.org\/10.1016\/j.bbmt.2019.10.017","journal-title":"Biol Blood Marrow Trans"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05557-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00277-023-05557-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-023-05557-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,17]],"date-time":"2024-02-17T11:16:47Z","timestamp":1708168607000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00277-023-05557-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11,25]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["5557"],"URL":"https:\/\/doi.org\/10.1007\/s00277-023-05557-z","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11,25]]},"assertion":[{"value":"4 January 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 November 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Data Management Committee of the TRUMP and the institutional ethics committee of Kyoto Prefectural University of Medicine (ERB-C-2164).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Patients or their parents gave written consent to undergoing transplantation and the use of medical records for research, in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}